SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr
SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial.
At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh Cancer Centre in the Western General Hospital, University of Edinburgh, Scotland UK, told the conference that after investigating the impact of adjuvant chest wall irradiation following mastectomy and axillary surgical staging in patients with operable breast cancer at a defined intermediate-risk of loco-regional recurrence the study had found no benefit.
The trial indicated with high precision that chest wall irradiation following mastectomy in patients with one to three positive nodes, or with node-negative breast cancer having other risk factors, had no impact on overall survival, and a clinically insignificant impact on chest wall recurrence.
After the conference, Kunkler discussed the findings with the Audio Journal of Oncology’s correspondent, Peter Goodwin:
PODCAST: Ian Kunkler in conversation with Peter Goodwin
SABCS 2024 Abstract GS2-03:
Kunkler I et al. “Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators”
https://sabcs.org/Portals/0/Documents/Embargoed/GS2-03%20Embargoed.pdf?ver=kXWlS2Nrc-7_KvwLiqBR1A%3D%3D
Comment
Kunkler I et al. Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigation. Abstract GS2-03. SABCS, 10-13 December, 2024.
Related Episodes
Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial
Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard
Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy
Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to node-negative after neoadjuvant chemotherapy do not require axillary lymph node dissection. Less invasive surgical staging procedures were found to be non-inferior in terms of three-year outcomes, irrespective of tumor type or initial stage.
Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.